We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01308203
Recruitment Status : Terminated (Merck has decided to discontinue all studies with extended-release niacin/laropiprant.because the HPS2-THRIVE did not meet its primary endpoint)
First Posted : March 4, 2011
Last Update Posted : August 19, 2015
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Daniel A. Siniawski, Hospital Italiano de Buenos Aires

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013